The ubiquitous nature of cancer: the role of the SCFFbw7 complex in development and transformation

被引：107

作者：

Crusio, K. M. ^{[1
,2
,3
]}

King, B. ^{[1
,2
,3
]}

Reavie, L. B. ^{[1
,2
,3
]}

Aifantis, I. ^{[1
,2
,3
]}

机构：

[1] NYU, Sch Med, Howard Hughes Med Inst, Dept Pathol, New York, NY 10016 USA

[2] NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA

[3] NYU, Sch Med, Helen & Martin S Kimmel Stem Cell Ctr, New York, NY 10016 USA

来源：

ONCOGENE | 2010年 / 29卷 / 35期

基金：

美国国家卫生研究院;

关键词：

Fbw7; ubiquitin-proteasome system; GSK-3; beta; p53; F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT DEGRADATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-DAMAGE-RESPONSE; CELL SELF-RENEWAL; C-MYC PROTEIN; TUMOR-SUPPRESSOR; CYCLIN-E; CHROMOSOMAL INSTABILITY; FBXW7; ACTS;

D O I：

10.1038/onc.2010.222

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The ubiquitin-proteasome system (UPS) is a multi-subunit pathway that allows for ubiquitin modification of proteins and leads to either degradation or other non-proteolytic processes such as trafficking or transcriptional activation. Given its role as a regulator of cellular homeostasis it is not surprising that members of the UPS are frequently aberrantly expressed in a number of disease states including cancer. This review will focus on one member of the UPS, the F-box protein, Fbw7 (also known as Sel-10, Ago, hCDC4) and mechanisms by which Fbw7 interacts with its substrates in the context of development and tumorigenesis will be discussed. In addition, antagonists of this pathway as well as current and future therapeutics for the UPS will be examined. Oncogene (2010) 29, 4865-4873; doi: 10.1038/onc.2010.222; published online 14 June 2010

引用

页码：4865 / 4873

页数：9

共 80 条

[1] FBXW7/hCDC4 is a general tumor suppressor in human cancer [J].